The US Food and Drug Administration (FDA) approved the first-ever anti-depression nasal spray, Spravato. The pharmaceutical company Johnson & Johnson created the spray from esketamine, a more potent ...

The U.S. has a much higher rate of maternal mortality than other high-income countries, and the risks are especially acute ...

Report with market evolution powered by AI - The global nicotine patch market size is estimated to grow by USD ...

Pregnant women who are incarcerated will move into the facility next week. For now, only women with 18 months or less to ...

"This program is going to give women the building blocks to live a better life, and then that is going to overflow into their ...

Johnson & Johnson’s seltorexant is one of two new therapies that the company reckons could become blockbuster treatments for depression, and data from a phase 3 trial keeps that hope alive.

In May of 1882, Congress codified these fears into law by passing the Chinese Exclusion Act, which banned Chinese people from ...

Shares in Axsome Therapeutics have rocketed on FDA approval of its depression therapy Auvelity ... That status goes to Johnson & Johnson's Spravato (esketamine), which was approved in March ...

Republicans in Colorado and Democrats nationally face challenges, with both parties in political disrepair and lacking public ...

Johnson & Johnson's ketamine-derived nasal spray has been approved as a standalone treatment to fight depression for those who had an inadequate response to oral antidepressants. It's hard to pin ...

A new study revealed that these programs may ... Study Finds New Link Between Food Choices, Depression and Alzheimer's Disease Feb. 5, 2025 — New research has shown that diet could influence the ...